Table 1. Group Comparison of Patients Demographics, UPDRS, and NMS Characteristics at Follow-up.
| Parkinson's Disease | Essential Tremor | PD vs ET at Follow-up | |||||
|---|---|---|---|---|---|---|---|
| Baseline n = 31 (%) | Follow-up n = 31 (%) | p Value | Baseline n = 22 (%) | Follow-up n = 21 (%) | p Value | p Value | |
| Age | 69.1±8.2 | 70.2±6.8 | 0.5 | 67.6±9.1 | 68.6±7.1 | 0.7 | 0.4 |
| Men | 22 (71) | 22 (71) | 1.0 | 12 (54) | 11 (52) | 1.0 | 1.0 |
| UPDRS-III | 27.0±12 | 16.5±8 | 0.0001 | 4.7±3 | 3.4±2 | 0.1 | <0.0001 |
| H & Y | ≤2 | ≤2 | - | - | - | - | - |
| Tremor | 22 (71) | 22 (71) | 1.0 | 22 (100) | 21 (100) | 1.0 | 0.007 |
| Dopaminergic therapy | 8 (26) | 31 (100) | <0.0001 | 1 (4) | 0 (0) | 1.0 | <0.0001 |
| Total LEDD (mg/day) | NA | 412±76 | - | 0 | 0 | - | - |
| l-dopa | 8 (26) | 25 (81) | <0.0001 | 1 (4) | 0 (0) | 1.0 | <0.0001 |
| NMS | 10.4±4.9 | 10.2±6.9 | 0.1 | 8.4±3.3 | 5±2.9 | 0.0009 | 0.002 |
Abbreviations: ET, Essential Tremor; H & Y: Hoehn & Yahr score; LEDD, l-dopa-equivalent Daily Dosage; NA, Not Available; NMS, Non-motor Symptoms; PD, Parkinson's Disease; UPDRS-III, Unified Parkinson's Disease Rating Scale.
Numbers in brackets indicate the percentage of patients in that subgroup. Significant p values are shown in bold.